Skip to main content
Figure 5 | Arthritis Research & Therapy

Figure 5

From: Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset

Figure 5

Comparison of the levels of various biomarkers in the SLE patient visits given PDN, MMF, and HCQ therapy at high or low dosage. Differences between doses of PDN (D, G, J, M), MMF (B, E, H, K, N), and HCQ (C, F, I, L, O) were not significant with the exception of SLEDAI (A), and in fact SLEDAI scores were higher for PDN dose of 20 to 60 mg/day compared to the 2 to 18 mg/day of dose. HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; PDN, prednisone; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us